Yi Lin
About
Yi Lin is a scholar working on Oncology, Molecular Biology and Hematology.
According to data from OpenAlex, Yi Lin has authored 299 papers receiving a total of 9.1k indexed citations (citations by other indexed papers that have themselves been cited), including 159 papers in Oncology, 74 papers in Molecular Biology and 65 papers in Hematology. Recurrent topics in Yi Lin's work include CAR-T cell therapy research (134 papers), Multiple Myeloma Research and Treatments (56 papers) and Lymphoma Diagnosis and Treatment (33 papers). Yi Lin is often cited by papers focused on CAR-T cell therapy research (134 papers), Multiple Myeloma Research and Treatments (56 papers) and Lymphoma Diagnosis and Treatment (33 papers). Yi Lin collaborates with scholars based in United States, China and France. Yi Lin's co-authors include Anna Solovey, Robert P. Hebbel, Daniel J. Weisdorf, Allan B. Dietz, Sattva S. Neelapu, Frederick L. Locke, Michael P. Gustafson, Peggy A. Bulur, William G. Wierda and Naval Daver and has published in prestigious journals such as New England Journal of Medicine, Journal of the American Chemical Society and Journal of Biological Chemistry.
In The Last Decade
Yi Lin
274 papers receiving 8.9k citations
Hit Papers
Author Peers
Peers are selected by citation overlap in the author's most active subfields. citations · hero ref
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Yi Lin | 4.9k | 3.8k | 2.0k | 1.8k | 1.3k | 299 | 9.1k | |
| Julie R. Park | 3.6k 0.7× | 3.3k 0.9× | 972 0.5× | 305 0.2× | 715 0.5× | 185 | 8.5k | |
| Torsten Tonn | 3.5k 0.7× | 2.9k 0.8× | 3.6k 1.8× | 1.0k 0.6× | 2.7k 2.1× | 162 | 9.7k | |
| Catriona Jamieson | 4.1k 0.8× | 6.7k 1.7× | 1.9k 1.0× | 3.4k 1.9× | 2.9k 2.2× | 187 | 12.2k | |
| Carmelo Carlo‐Stella | 3.0k 0.6× | 2.4k 0.6× | 2.1k 1.0× | 2.4k 1.4× | 3.4k 2.6× | 350 | 9.1k | |
| Pablo Menéndez | 1.4k 0.3× | 5.1k 1.3× | 706 0.3× | 1.2k 0.7× | 1.2k 0.9× | 233 | 8.1k | |
| Jane L. Liesveld | 2.3k 0.5× | 2.8k 0.7× | 1.6k 0.8× | 3.7k 2.1× | 1.4k 1.1× | 252 | 8.3k | |
| Ulrich Dührsen | 3.0k 0.6× | 2.2k 0.6× | 3.2k 1.6× | 3.1k 1.7× | 3.3k 2.5× | 283 | 10.3k | |
| Steven M. Devine | 3.4k 0.7× | 2.2k 0.6× | 3.0k 1.5× | 6.1k 3.4× | 3.1k 2.4× | 318 | 11.0k | |
| Josef Vormoor | 3.5k 0.7× | 3.2k 0.8× | 1.5k 0.7× | 2.7k 1.5× | 938 0.7× | 117 | 7.8k | |
| Ivan Borrello | 7.3k 1.5× | 3.3k 0.9× | 7.3k 3.6× | 3.5k 2.0× | 916 0.7× | 148 | 13.0k |
Countries citing papers authored by Yi Lin
Since
Specialization
Citations
This map shows the geographic impact of Yi Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yi Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yi Lin more than expected).
Fields of papers citing papers by Yi Lin
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Yi Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yi Lin. The network helps show where Yi Lin may publish in the future.
Co-authorship network of co-authors of Yi Lin
This figure shows the co-authorship network connecting the top 25 collaborators of Yi Lin. A scholar is included among the top collaborators of Yi Lin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yi Lin. Yi Lin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Isufi, Iris, Jennifer L. Crombie, Matthew J. Frigault, et al.. (2025). Effectiveness and Safety Outcomes of Standard of Care (SOC) Lisocabtagene Maraleucel (liso-cel) in Patients (Pts) with Relapsed or Refractory (R/R) Transformed Large B-Cell Lymphoma (tLBCL): Results from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry. Transplantation and Cellular Therapy. 31(2). S215–S215.
2.
Binder, Moritz, Joselle Cook, Morie A. Gertz, et al.. (2025). The ratio of brain to liver glucose activity and disease activity in multiple myeloma. Blood Cancer Journal. 15(1). 90–90.
3.
Cook, Joselle, Rahma Warsame, Francis K. Buadi, et al.. (2025). Interleukin-6 is a highly prognostic biomarker for POEMS syndrome. Leukemia. 39(9). 2281–2284.
4.
Abbasi, Muhannad, Yi Lin, Jonas Paludo, et al.. (2024). Baseline echocardiographic variables as predictors of hemodynamically significant cytokine release syndrome in adults treated with CD19 CAR T-cell therapy for hematological malignancies. Cardio-Oncology. 10(1). 91–91.
5.
Gile, Jennifer, Matthew J. Maurer, Gordon Ruan, et al.. (2024). Low magnesium levels and prognosis in newly diagnosed diffuse large B-cell lymphoma. The Oncologist. 29(12). e1779–e1782.
6.
Wickland, Daniel P., Erik Jessen, Brian M. Necela, et al.. (2024). Comprehensive profiling of cancer neoantigens from aberrant RNA splicing. Journal for ImmunoTherapy of Cancer. 12(5). e008988–e008988.
7.
Saifi, Omran, Scott C. Lester, William G. Breen, et al.. (2023). Incorporating radiation with anti‐CD19 chimeric antigen receptor T‐cell therapy for relapsed/refractory non‐Hodgkin lymphoma: A multicenter consensus approach. American Journal of Hematology. 99(1). 124–134.
8.
Zhang, Jinwen, Xiaorui Liu, Lin Rao, et al.. (2023). Adverse obstetric and perinatal outcomes of patients with history of recurrent miscarriage: a retrospective cohort study. Fertility and Sterility. 120(3). 626–634.
9.
Rejeski, Kai, Doris K. Hansen, Yucai Wang, et al.. (2023). Applying the Novel EHA/EBMT Grading System for Icaht Following CAR-T Therapy: Comparative Incidence across Disease Entities and Association with Infections and Mortality. Blood. 142(Supplement 1). 359–359.
10.
Bansal, Radhika, Jeremy T. Larsen, Matthew Hathcock, et al.. (2023). Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma. Blood Cancer Journal. 13(1). 47–47.
11.
Rejeski, Kai, Yucai Wang, Omar Albanyan, et al.. (2023). The CAR‐HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL . American Journal of Hematology. 98(11). 1699–1710.
12.
Abdallah, Nadine, Alexandra N. Smith, Susan M. Geyer, et al.. (2023). Conditional survival in multiple myeloma and impact of prognostic factors over time. Blood Cancer Journal. 13(1). 78–78.
13.
Bansal, Radhika, Jeremy T. Larsen, Matthew Hathcock, et al.. (2022). Prognostic Value of Early Bone Marrow MRD Status in CAR-T Therapy for Myeloma. Transplantation and Cellular Therapy. 28(3). S186–S187.
14.
Ye, Shuting, et al.. (2022). LncRNA OR2A1‐AS1 index predicts survival in germinal center‐like diffuse large B‐cell lymphoma. Journal of Clinical Laboratory Analysis. 36(10). e24680–e24680.
15.
Iqbal, Madiha, Radhika Bansal, Allison Rosenthal, et al.. (2022). Impact of Rituximab and Corticosteroids on Late Cytopenias Post-Chimeric Antigen Receptor T Cell Therapy. Transplantation and Cellular Therapy. 28(10). 668.e1–668.e6.
16.
Khurana, Arushi, Matthew Hathcock, Thomas M. Habermann, et al.. (2021). Lines of Therapy before Autologous Stem Cell Transplant (ASCT) and CAR-T Infusion Affect Outcomes in Aggressive Non-Hodgkin’s Lymphoma (NHL). Transplantation and Cellular Therapy. 27(3). S45–S47.
17.
Berdeja, Jesús G., Noopur Raje, David S. Siegel, et al.. (2021). Efficacy and Safety of Idecabtagene Vicleucel (ide-cel, bb2121) in Elderly Patients with Relapsed and Refractory Multiple Myeloma: KarMMa Subgroup Analysis. Transplantation and Cellular Therapy. 27(3). S397–S398.
18.
Gustafson, Michael P., Yi Lin, Jonathan Bleeker, et al.. (2015). Intratumoral CD14+ Cells and Circulating CD14+HLA-DRlo/neg Monocytes Correlate with Decreased Survival in Patients with Clear Cell Renal Cell Carcinoma. Clinical Cancer Research. 21(18). 4224–4233.
19.
Leung, Nelson, Shaji Kumar, Siobhán Glavey, et al.. (2015). The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation. Nephrology Dialysis Transplantation. 31(8). 1284–1289.
20.
Kapoor, Prashant, Shaji Kumar, Angela Dispenzieri, et al.. (2013). Importance of Achieving Stringent Complete Response After Autologous Stem-Cell Transplantation in Multiple Myeloma. Journal of Clinical Oncology. 31(36). 4529–4535.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Julie R. Park Breakdown of academic impact, for papers by Torsten Tonn Breakdown of academic impact, for papers by Catriona Jamieson Breakdown of academic impact, for papers by Carmelo Carlo‐Stella Breakdown of academic impact, for papers by Pablo Menéndez Breakdown of academic impact, for papers by Jane L. Liesveld Breakdown of academic impact, for papers by Ulrich Dührsen Breakdown of academic impact, for papers by Steven M. Devine Breakdown of academic impact, for papers by Josef Vormoor Breakdown of academic impact, for papers by Ivan Borrello